Viscosupplementation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

A recent industry analysis report by Fairfield Market Research has unveiled groundbreaking insights into the Viscosupplementation Market. In 2024, global sales of Viscosupplementation products reached a remarkable US$ 5.5 billion, setting the stage for unprecedented growth in the coming years. Projections indicate that from 2024 to 2031, the Viscosupplementation Market is poised to experience a staggering CAGR, far surpassing historical growth rates. The single injection segment is expected to be the highest revenue generator, with an absolute dollar opportunity during the period of 2024 to 2031.

Factors Fueling the Viscosupplementation Market Surge

Several factors are driving the impressive growth of the Viscosupplementation Market. Rising demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-related disorders, and advancements in hyaluronic acid-based therapies are key drivers of this remarkable expansion. Viscosupplements have proven clinical efficacy and are considered the most effective therapy for knee osteoarthritis, a leading cause of chronic disability. With the global population of individuals aged 65 and older expected to double by 2050, leading to increased rates of obesity and osteoarthritis, the market for alternate corticosteroid treatment options for joint pain management is set to soar.

Favorable Reimbursement Policies and Innovation Pave the Way

In the United States and France, favorable reimbursement policies for Viscosupplementation treatments are expected to create opportunities for key market players. FDA-approved Class III medical devices such as Orthovisc, Supartz Hyalgan, and Synvisc enjoy coverage by Medicaid, Medicare, and other state-funded healthcare programs. In France, Social Security reimburses a substantial portion of the treatment costs, providing a promising landscape for market expansion.

Moreover, innovation continues to drive the Viscosupplementation Market forward. Companies like Bone Therapeutics S.A. have completed clinical studies for JTA-004 intra-articular injections for knee osteoarthritis, while Anika Therapeutics, Inc. introduced Hyalofast, a hyaluronic acid-based cartilage repair scaffold, demonstrating the commitment to advancing therapies in this field.

Regional Opportunities

The Asia Pacific region is expected to offer the most significant growth potential during the forecast period, driven by rising demand for Viscosupplementation in developing countries, especially India and China. Asia Pacific accounted for over 45% of the market's revenue share in 2020, propelled by an aging population susceptible to osteoarthritis.

Country-Specific Analysis

U.S. Viscosupplementation Market: The United States market is on an upward trajectory, fueled by a growing preference for shorter treatment regimens and an increasing prevalence of osteoarthritis. The market is poised to register substantial growth and absolute dollar opportunities between 2024 and 2031.

U.K. Viscosupplementation Market: The U.K. market is expected to experience substantial growth from 2024 to 2031, and a significant absolute dollar opportunity.

Japan Viscosupplementation Market: Japan is poised to see robust growth, resulting in a substantial absolute dollar opportunity.

South Korea Viscosupplementation Market: The market in South Korea is expected to expand steadily during the forecast period, and a notable absolute dollar opportunity.

Key Players in the Market

Prominent players in the Viscosupplementation Market include: Sanofi, Anika Therapeutics, Inc., Seikagaku Corp., Zimmer Biomet, Smith & Nephew PLC, Ferring Pharmaceuticals B.V., Lifecore Biomedical, LG Life Sciences Ltd., Fidia Farmaceutici S.p.A., and F.Hoffmann-La Roche Ltd.

Market Segments Covered in Viscosupplementation Market Industry Analysis

By Product Type

Single Injection
Three Injection
Five Injection

By End User

Hospitals
Orthopaedic Clinics/Ambulatory Surgical Centres (ASCs)

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Viscosupplementation Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Viscosupplementation Market Outlook, 2018 - 2031

3.1. Global Viscosupplementation Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Single Injection
  - 3.1.1.2. Three Injection
  - 3.1.1.3. Five Injection
3.2. Global Viscosupplementation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospitals
  - 3.2.1.2. Orthopaedic Clinics/Ambulatory Surgical Centres (ASCs)
3.3. Global Viscosupplementation Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Viscosupplementation Market Outlook, 2018 - 2031

4.1. North America Viscosupplementation Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Single Injection
  - 4.1.1.2. Three Injection
  - 4.1.1.3. Five Injection
4.2. North America Viscosupplementation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospitals
  - 4.2.1.2. Orthopaedic Clinics/Ambulatory Surgical Centres (ASCs)
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Viscosupplementation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Viscosupplementation Market Outlook, 2018 - 2031

5.1. Europe Viscosupplementation Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Single Injection
  - 5.1.1.2. Three Injection
  - 5.1.1.3. Five Injection
5.2. Europe Viscosupplementation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospitals
  - 5.2.1.2. Orthopaedic Clinics/Ambulatory Surgical Centres (ASCs)
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Viscosupplementation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Viscosupplementation Market Outlook, 2018 - 2031

6.1. Asia Pacific Viscosupplementation Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Single Injection
  - 6.1.1.2. Three Injection
  - 6.1.1.3. Five Injection
6.2. Asia Pacific Viscosupplementation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospitals
  - 6.2.1.2. Orthopaedic Clinics/Ambulatory Surgical Centres (ASCs)
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Viscosupplementation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Viscosupplementation Market Outlook, 2018 - 2031

7.1. Latin America Viscosupplementation Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Single Injection
  - 7.1.1.2. Three Injection
  - 7.1.1.3. Five Injection
7.2. Latin America Viscosupplementation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Viscosupplementation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Viscosupplementation Market Outlook, 2018 - 2031

8.1. Middle East & Africa Viscosupplementation Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Single Injection
  - 8.1.1.2. Three Injection
  - 8.1.1.3. Five Injection
8.2. Middle East & Africa Viscosupplementation Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospitals
  - 8.2.1.2. Orthopaedic Clinics/Ambulatory Surgical Centres (ASCs)
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Viscosupplementation Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Viscosupplementation Market by Product Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Viscosupplementation Market by End User, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by End User Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Sanofi
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Anika Therapeutics, Inc.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Seikagaku Corp.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Zimmer Biomet
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Smith & Nephew PLC
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Ferring Pharmaceuticals B.V.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Lifecore Biomedical
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. LG Life Sciences Ltd.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Fidia Farmaceutici S.p.A
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. F.Hoffmann-La Roche Ltd.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations